MCL treatment algorithm. ASCT, autologous stem cell transplantation; BR, bendamustine and rituximab; BTKi, Bruton’s tyrosine kinase inhibitor; LDH, lactate dehydrogenase; PS, performance status; RBAC, rituximab, bendamustine, and cytarabine; RCHOP, rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone; RDHAP, rituximab, dexamethasone, cytarabine, and cisplatin; RHiDAC, rituximab, high-dose cytarabine; R-maxi-CHOP, dose intensified cyclophosphamide, doxorubicin, vincristine, prednisone; VRCAP, cyclophosphamide, doxorubicin, bortezomib, and prednisone.